Handelsbanken Fonder AB Grows Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Handelsbanken Fonder AB grew its position in Amgen Inc. (NASDAQ:AMGN) by 1.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 367,586 shares of the medical research company’s stock after buying an additional 3,830 shares during the quarter. Handelsbanken Fonder AB owned 0.07% of Amgen worth $105,872,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of AMGN. Vanguard Group Inc. increased its stake in Amgen by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 49,035,981 shares of the medical research company’s stock worth $13,178,910,000 after buying an additional 165,636 shares during the period. Morgan Stanley boosted its holdings in Amgen by 12.9% in the fourth quarter. Morgan Stanley now owns 13,301,365 shares of the medical research company’s stock valued at $3,493,471,000 after purchasing an additional 1,523,665 shares during the period. Charles Schwab Investment Management Inc. grew its stake in Amgen by 1.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 8,819,690 shares of the medical research company’s stock worth $2,132,778,000 after purchasing an additional 94,565 shares in the last quarter. Moneta Group Investment Advisors LLC increased its holdings in Amgen by 83,875.6% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 7,541,011 shares of the medical research company’s stock worth $1,980,571,000 after purchasing an additional 7,532,031 shares during the period. Finally, Northern Trust Corp raised its position in Amgen by 3.8% in the 3rd quarter. Northern Trust Corp now owns 6,977,625 shares of the medical research company’s stock valued at $1,875,306,000 after purchasing an additional 255,463 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

AMGN has been the topic of several analyst reports. UBS Group reduced their target price on shares of Amgen from $314.00 to $284.00 and set a “neutral” rating on the stock in a report on Wednesday. Truist Financial reissued a “buy” rating and issued a $320.00 target price on shares of Amgen in a report on Friday, April 12th. StockNews.com cut Amgen from a “buy” rating to a “hold” rating in a research report on Thursday, March 28th. TD Cowen decreased their target price on Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a research note on Wednesday. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $329.00 price target on shares of Amgen in a research note on Wednesday, April 3rd. Ten investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $296.95.

Amgen Price Performance

Shares of AMGN stock traded up $6.18 during midday trading on Friday, reaching $268.93. 3,380,330 shares of the company traded hands, compared to its average volume of 2,077,465. The firm’s 50 day simple moving average is $276.90 and its two-hundred day simple moving average is $281.40. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. The firm has a market cap of $144.25 billion, a PE ratio of 21.53, a price-to-earnings-growth ratio of 2.50 and a beta of 0.58. Amgen Inc. has a 1-year low of $211.71 and a 1-year high of $329.72.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.66 by $0.05. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The business had revenue of $8.20 billion during the quarter, compared to the consensus estimate of $8.13 billion. During the same quarter in the previous year, the company posted $4.09 EPS. The business’s revenue was up 19.8% on a year-over-year basis. On average, equities research analysts expect that Amgen Inc. will post 19.45 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be paid a $2.25 dividend. This represents a $9.00 annualized dividend and a yield of 3.35%. The ex-dividend date is Thursday, May 16th. Amgen’s payout ratio is 72.06%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.